ACAD vs. BLZE
ACAD (ACADIA Pharmaceuticals Inc.) and BLZE (Backblaze, Inc.) are both stocks. ACAD operates in Biotechnology (Healthcare), while BLZE operates in Software - Infrastructure (Technology). Over the past 3 years, ACAD returned -7.46%/yr vs 44.46%/yr for BLZE. At a 0.29 correlation, their price movements are largely independent.
Performance
ACAD vs. BLZE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ACAD achieves a -4.53% return, which is significantly lower than BLZE's 247.42% return.
ACAD
- 1D
- -2.75%
- 1M
- 20.91%
- 6M
- -4.10%
- YTD
- -4.53%
- 1Y
- 21.54%
- 3Y*
- -7.46%
- 5Y*
- 1.71%
- 10Y*
- -2.55%
BLZE
- 1D
- -8.01%
- 1M
- 104.42%
- 6M
- 214.37%
- YTD
- 247.42%
- 1Y
- 213.76%
- 3Y*
- 44.46%
- 5Y*
- —
- 10Y*
- —
ACAD vs. BLZE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
ACAD ACADIA Pharmaceuticals Inc. | -4.53% | 45.56% | -41.39% | 96.67% | -31.79% | 14.75% |
BLZE Backblaze, Inc. | 247.42% | -22.59% | -20.69% | 23.41% | -63.59% | -11.11% |
Correlation
The correlation between ACAD and BLZE is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.26 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since Nov 11, 2021 | 0.29 |
Fundamentals
ACAD:
$4.37B
BLZE:
$971.64M
ACAD:
$2.19
BLZE:
-$0.39
ACAD:
3.99
BLZE:
6.21
ACAD:
3.53
BLZE:
11.34
ACAD:
$1.10B
BLZE:
$149.89M
ACAD:
$758.58M
BLZE:
$93.07M
ACAD:
$104.56M
BLZE:
-$899.00K
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ACAD vs. BLZE — Risk / Return Rank
ACAD
BLZE
ACAD vs. BLZE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and Backblaze, Inc. (BLZE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ACAD | BLZE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.49 | ||
| Sortino ratioReturn per unit of downside risk | -2.22 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.49 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | 0.78 | 3.11 | -2.32 |
| Martin ratioReturn relative to average drawdown | 1.38 | 5.00 | -3.62 |
Loading charts...
Drawdowns
ACAD vs. BLZE - Drawdown Comparison
The maximum ACAD drawdown since its inception was -96.29%, which is greater than BLZE's maximum drawdown of -89.49%. Use the drawdown chart below to compare losses from any high point for ACAD and BLZE.
Loading charts...
Drawdown Indicators
| ACAD | BLZE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.29% | -89.49% | -6.80% |
Max Drawdown (1Y)Largest decline over 1 year | -27.58% | -69.21% | +41.63% |
Max Drawdown (3Y)Largest decline over 3 years | -57.87% | -72.02% | +14.15% |
Max Drawdown (5Y)Largest decline over 5 years | -57.87% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -77.18% | — | — |
Current DrawdownCurrent decline from peak | -55.26% | -48.60% | -6.66% |
Average DrawdownAverage peak-to-trough decline | -50.27% | -77.17% | +26.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.70% | 42.95% | -27.25% |
Volatility
ACAD vs. BLZE - Volatility Comparison
The current volatility for ACADIA Pharmaceuticals Inc. (ACAD) is 9.68%, while Backblaze, Inc. (BLZE) has a volatility of 39.65%. This indicates that ACAD experiences smaller price fluctuations and is considered to be less risky than BLZE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ACAD | BLZE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.68% | 39.65% | -29.97% |
Volatility (6M)Calculated over the trailing 6-month period | 26.81% | 74.21% | -47.40% |
Volatility (1Y)Calculated over the trailing 1-year period | 37.31% | 104.15% | -66.84% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 55.38% | 84.76% | -29.38% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 61.84% | 84.76% | -22.92% |
Dividends
ACAD vs. BLZE - Dividend Comparison
Neither ACAD nor BLZE has paid dividends to shareholders.
Financials
ACAD vs. BLZE - Financials Comparison
This section allows you to compare key financial metrics between ACADIA Pharmaceuticals Inc. and Backblaze, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ACAD vs. BLZE - Profitability Comparison
ACAD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, ACADIA Pharmaceuticals Inc. reported a gross profit of 0.00 and revenue of 268.06M. Therefore, the gross margin over that period was 0.0%.
BLZE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Backblaze, Inc. reported a gross profit of 23.53M and revenue of 38.67M. Therefore, the gross margin over that period was 60.9%.
ACAD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, ACADIA Pharmaceuticals Inc. reported an operating income of -4.62M and revenue of 268.06M, resulting in an operating margin of -1.7%.
BLZE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Backblaze, Inc. reported an operating income of -5.35M and revenue of 38.67M, resulting in an operating margin of -13.8%.
ACAD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, ACADIA Pharmaceuticals Inc. reported a net income of 3.64M and revenue of 268.06M, resulting in a net margin of 1.4%.
BLZE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Backblaze, Inc. reported a net income of -6.15M and revenue of 38.67M, resulting in a net margin of -15.9%.
Frequently Asked Questions
ACAD and BLZE have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BLZE has higher volatility (39.65%) compared to ACAD (9.68%). In terms of maximum drawdown, ACAD dropped -96.29% vs BLZE's -89.49%.
BLZE currently has the higher Sharpe Ratio (2.07 vs 0.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ACAD and BLZE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer